

Date: 10-06-2026

To
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Mumbai - 400 051

Ref: BSE Scrip Code: 533259; NSE Symbol: HEALTHX

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached herewith the Investor Presentation of the Company.

This is for your information and record.

Thanking you,

Yours faithfully,

For Health X Platform Limited
(formerly known as Sastasundar Ventures Limited)

Pratap Singh
Company Secretary & Compliance Officer
M. No.: ACS-24081

Encl: As Above

Investor Presentation

Simplification of Corporate
Structure

June 2026



Safe Harbour

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Health X Platform Limited (erstwhile Sastasundar Ventures Limited) (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

Contents


- ☑ Current Group Structure
- ☑ Proposed Composite Scheme
- ☑ Effect of Scheme on Public Shareholders
- ☑ Post Scheme Group Structure
- ☑ Pre – Post Shareholding Pattern
- ☑ Key Indicative Timelines



Current Group Structure




- Health X Platform Limited (“**Health X**”) presently operates through several subsidiaries only, focusing largely on the following business segments:
 - ✓ Healthcare services (including pharmaceutical trading, distribution, and e-commerce sale of medicines and diagnostics) and;
 - ✓ Financial services (including lending, investments, wealth management and advisory services).
- Sastasundar Healthbuddy Limited (“**SHBL**”) is principally engaged in the business of trading and distribution of medicine and other pharmaceutical products to various retailers. SHBL also operates an E-commerce platform for sale of medicines, other pharmaceuticals products and diagnostics, through its subsidiary. SHBL is a material subsidiary of Health X.
- Microsec Resources Private Limited (“**MRL**”), a registered Non-Deposit Accepting Non-Banking Financial Institution (“**NBFI**”), is involved in business of financing. MRL is a wholly owned subsidiary of Health X.
- Innogrow Technologies Limited (“**ITL**”) was incorporated to principally engage in the business of providing end-to-end IT, digital technology services and IT-enabled services. Innogrow is a wholly owned subsidiary of Health X.



Proposed Composite Scheme



Key Objectives



To consolidate the Healthcare Services business into a single entity, enabling efficient resource utilization and enhanced shareholder value.




To create a focused and independent Financial Services entity, value unlocking, and thereby, having independent group structure for each of the business segments of the group.



To consolidate and streamline the group structure by combining the businesses and resources of the companies into a single entity.



To provide greater strategic focus and operational independence for each business segment, enabling more effective decision-making and capital deployment.



Part 1


Demerger of finance undertaking of Health X into MRL.

- Health X to demerge its finance business to MRL.
- MRL to issue shares to shareholders of Health X in 1:3 ratio.
- Pursuant to demerger, shares held by Health X in MRL shall be cancelled.
- Shareholding of MRL* shall mirror the shareholding of Health X.
**MRL will be converted into a Public company and the shares of MRL would be listed on BSE and NSE pursuant to Scheme.*

Pursuant to demerger of the Financial Undertaking from Health X to MRL, MRL shall issue and allot to the shareholders of Health X, 1 (One) equity share of INR 10 each of MRL for every 3 (Three) equity shares of INR 10 each held in Health X.

The following number of shares shall be issued as consideration for demerger:


Particulars	No. of shares of MRL to be allotted
Promoter shareholders of Health X	78,53,542
Public shareholders of Health X	27,49,958
Total	1,06,03,500



Part 2

Amalgamation of Innogrow Technologies into Microsec Resources Private Limited

- Post Demerger of finance undertaking from Health X to MRL, ITL will become the wholly owned subsidiary of MRL.
- ITL is proposed to be merged with MRL.
- No shares shall be issued by MRL pursuant to the said amalgamation, as ITL is a wholly owned subsidiary of MRL.



Part 3

Merger of SHBL into Health X

- SHBL to be merged into Health X.
- The shares proposed to be issued by Health X to the shareholders of SHBL pursuant to merger shall also be listed on the Stock Exchange.
- Post demerger to MRL, Health X's only significant asset will be its 78.89% equity stake in SHBL. This entire shareholding in SHBL will be cancelled, and the other shareholders of SHBL will be allotted equity shares in Health X.

Pursuant to merger of SHBL with Health X, Health X shall issue and allot to the other shareholders of SHBL, 85,12,168 equity shares of INR 10 each of Health X, for 45,75,830 equity shares of INR 10 each held in SHBL.

The following number of shares shall be issued as consideration for merger:


Particulars	No. of shares of Health X to be allotted
Promoter shareholders of SHBL	-
Public shareholders of SHBL	85,12,168
Total	85,12,168

Effect of Scheme on Public Shareholders




Value Preservation and Enhancement:

The proposed Composite Scheme of Arrangement and Amalgamation ensures that the value of investments held by existing public shareholders is completely protected and, in fact, positioned for greater growth. The Board of Directors, Audit Committee and the Committee of Independent Directors have rigorously evaluated the Scheme and concluded that it is strictly equitable and not detrimental to the interests of any public shareholder.



Post Scheme Group Structure





Pre – Post Shareholding Pattern



Shareholding Pattern of Health X

Category of Shareholder	Pre Scheme		Post Scheme	
	No. of shares	%	No. of shares	%
Promoter	2,35,60,627	74.07%	2,35,60,627	58.43%
Public	82,49,873	25.93%	1,67,62,041	41.57%
Total	3,18,10,500	100%	4,03,22,668	100%

Shareholding Pattern of SHBL

Category of Shareholder	Pre Scheme		Post Scheme	
	No. of shares	%	No. of shares	%
Promoter	1,71,00,160	78.89%	Not Applicable – SHBL shall be dissolved pursuant to Scheme.	
Public	45,75,830	21.11%		
Total	2,16,75,990	100%		

Shareholding Pattern of MRL


Category of Shareholder	Pre Scheme		Post Scheme	
	No. of shares	%	No. of shares	%
Promoter	25,81,357	100%	78,53,542	74.07%
Public	-	-	27,49,958	25.93%
Total	25,81,357	100%	1,06,03,500	100%

Shareholding Pattern of ITL

Category of Shareholder	Pre Scheme		Post Scheme	
	No. of shares	%	No. of shares	%
Promoter	3,31,018	100%	Not Applicable – ITL shall be dissolved pursuant to Scheme.	
Public	-	-		
Total	3,31,018	100%		

Key Indicative Timelines





Implementation of the scheme is expected to take around 12 – 14 months subject to the receipt of the requisite approvals.

Thank You

